Ontology highlight
ABSTRACT:
SUBMITTER: Costa C
PROVIDER: S-EPMC4745884 | biostudies-literature | 2015 Jan
REPOSITORIES: biostudies-literature
Costa Carlotta C Ebi Hiromichi H Martini Miriam M Beausoleil Sean A SA Faber Anthony C AC Jakubik Charles T CT Huang Alan A Wang Youzhen Y Nishtala Madhuri M Hall Ben B Rikova Klarisa K Zhao Jean J Hirsch Emilio E Benes Cyril H CH Engelman Jeffrey A JA
Cancer cell 20141224 1
BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (p110a), is currently in clinical trials for the treatment of solid tumors, especially luminal breast cancers with PIK3CA mutations and/or HER2 amplification. This study reveals that, even among these sensitive cancers, the initial efficacy of p110α inhibition is mitigated by rapid re-accumulation of the PI3K product PIP3 produced by the p110β isoform. Importantly, the reactivation ...[more]